FDA: Roche drug works in early-stage cancer

Published: Tuesday, Sept. 10, 2013 5:41 p.m. CDT

WASHINGTON (AP) – The Food and Drug Administration has issued a positive review of a breast cancer drug from Roche that soon could become the first pharmaceutical option approved for treating early-stage disease before surgery.

FDA scientists said women who received the drug Perjeta as initial treatment for breast cancer were more likely to be cancer-free at the time of surgery than women who received older drug combinations. Although the results come from mid-stage trials of the drug, FDA scientists recommended accelerating approval of the drug – a step reserved for groundbreaking drugs to treat life-threatening diseases.

Perjeta was first approved last summer to treat women with a subtype of breast cancer that already has spread. But Roche’s Genentech unit now is seeking approval to use the drug at a much earlier stage of the disease: after diagnosis and before surgery to remove the tumor.

The FDA is scheduled to make a decision on whether to approve Perjeta for early-stage breast cancer by Oct. 31.

Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Reader Poll

What's your favorite part of spring?
Trees budding
Birds chirping
Kids playing
Grilling out
Other